NEW YORK, February 24, 2017 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com explores the Biotecharena with the following companies in focus: Puma Biotechnology Inc. (NASDAQ: PBYI), Dipexium Pharmaceuticals Inc. (NASDAQ: DPRX), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and CTI BioPharma Corp. (NASDAQ: CTIC). These stocks belong to the Healthcare
On Thursday, shares in Los Angeles, California headquartered Puma Biotechnology Inc. recorded a trading volume of 537,455 shares. The stock ended the session 1.17% higher at $34.70. The Company's shares have gained 6.28% in the last one month and 13.03% on an YTD basis. The stock is trading 0.96% above its 50-day moving average. Moreover, shares of Puma Biotechnology, which focuses on the development and commercialization of products for the treatment of various forms of cancer, have a Relative Strength Index (RSI) of 48.72.
On January 06th, 2017, Puma Biotechnology announced that it has expanded the fourth cohort from its Phase-II SUMMIT clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). The cohort that has been expanded is the cohort that includes patients with metastatic cervical cancer and whose tumors have a HER2 mutation. Your complete research report on PBYI can be retrieved for free at:
New York-based Dipexium Pharmaceuticals Inc.'s stock closed the day flat at $1.25 with a total trading volume of 80,949 shares. The Company's shares are trading 14.06% below their 50-day moving average. Shares of the company, which focuses on the development and commercialization of antibiotics in the US, have an RSI of 40.36.
On February 14th, 2017, PLx Pharma Inc. announced that the results of a 40-subject pharmacokinetic/pharmacodynamic trial of Aspertec™, a novel, patent-protected, lipid-based aspirin product, have been published by the prestigious, peer-reviewed Journal of the American College of Cardiology. On December 22nd, 2016, PLx announced that it had entered into a merger agreement with Dipexium Pharmaceuticals. Following the closing of the merger, which is subject to a number of conditions precedent, including approval of both PLx and Dipexium stockholders, it is expected that Dipexium will be renamed "PLx Pharma Inc." and will operate under the leadership of the PLx management team. A free report on DPRX is just a click away at:
Shares in Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc. recorded a trading volume of 1.17 million shares, which was higher than their three months average volume of 966,730 shares. The stock ended yesterday's trading session 4.44% lower at $5.60. The Company's shares are trading above their 200-day moving average by 22.02%. Furthermore, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have an RSI of 41.95.
On February 15th, 2017, BioCryst Pharmaceuticals announced that its Q4 and full year 2016 financial results will be released on February 27th, 2017. BioCryst will host a conference call and webcast at 9:00 a.m. ET to discuss financial results and to provide an update regarding its clinical development programs.
On February 16th, 2017, research firm Ladenburg Thalmann initiated a 'Buy' rating on the Company's stock, with a target price of $11 per share. Sign up for your complimentary research report on BCRX at:
Seattle, Washington headquartered CTI BioPharma Corp.'s stock finished Thursday's session 0.70% lower at $4.25, with a total trading volume of 129,705 shares. The Company's shares have skyrocketed 962.23% over the previous three months and 942.69% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 20.25% and 260.84%, respectively. Additionally, shares of CTI BioPharma, which engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the US and internationally, have an RSI of 52.70.
On February 23rd, 2017, CTI BioPharma announced that management plans to report its Q4 and full year 2016 financial results on March 02nd, 2017, after the close of the US financial markets. Following the announcement, members of the Company's management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET. Register for free on Stock-Callers.com and download the latest research report on CTIC at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!